Bio-Rad and Enzon Announce Marketing Agreement
Companies Join Forces to Promote Diagnostic Test for Invasive Aspergillosis
Bio-Rad laboratories, Inc. , a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced that it has entered into a marketing agreement with Enzon Pharmaceuticals, Inc. to co-promote Bio-Rad's PlateliaTM Aspergillus EIA test kit in the United States and Canada. The test is the only FDA-cleared method for diagnosing Invasive aspergillosis.
Invasive Aspergillosis is an opportunistic fungal infection that leads to high mortality rates in immunocompromised patients such as those suffering from cancer, HIV and recipients of bone marrow and solid organ transplants. While the infection is difficult to diagnose using traditional laboratory methods which are often invasive, time-consuming and lack the sensitivity needed to produce conclusive results, Bio-Rad's Aspergillus test provides fast, highly accurate results. This breakthrough test received U.S. Food and Drug Administration (FDA) clearance in May 2003.
"We are pleased to be able to partner with Enzon to offer laboratories and physicians a dramatic improvement to traditional methods of diagnosing Invasive Aspergillosis," said John Goetz, Bio-Rad Vice President of Clinical Diagnostics.
"The combination of Bio-Rad's powerful diagnostic tool with ABELCET's proven track record as an effective antifungal agent will enable our sales team to provide physicians with a premier package aimed at total patient care," said Clarke Atwell, Enzon Vice President of Sales and Marketing.
Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.
Enzon Pharmaceuticals, Inc. (www.enzon.com) is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The company is headquartered in Bridgewater, New Jersey.
Various statements made within this press release may constitute "forward- looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward- looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.
Source: Bio-Rad Laboratories, Inc.
Other news from the department business & finance
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
